Aptamers Market, by Type (Nucleic Acid, (DNA-based Aptamers, RNA-based Aptamers, XNA-based Aptamers), Peptide Aptamers), by Application (Diagnostics, Therapeutics, Research and Development), by End User (Biotechnology and Pharmaceutical Companies, Academi

Aptamers Market, by Type (Nucleic Acid, (DNA-based Aptamers, RNA-based Aptamers, XNA-based Aptamers), Peptide Aptamers), by Application (Diagnostics, Therapeutics, Research and Development), by End User (Biotechnology and Pharmaceutical Companies, Academic and Research Institutions, Contract Research Organization), and by Region (North America, Latin America, Europe, Asia Pacific, Middle East, and Africa) - Size, Share, Outlook, and Opportunity Analysis, 2022 - 2030

Aptamers are short single-stranded DNA or RNA (ssDNA or ssRNA) molecules that bind to a specific target protein, lipid, or nucleic acid molecules with high specificity. Aptamers can also be conjugated to drugs, and work as drug-delivery systems. For example, aptamers have been conjugated with chemotherapy drugs to turn target and bind to only cancerous cells and leave healthy tissue untouched. Furthermore, factors such as lesser possibility of provoking undesired immune responses, high thermal stability, and cost-efficiency provide are expected to boost demand for aptamers. These are produced through a technique called Systematic Evolution of Ligands by Exponential enrichment (SELEX), which is time-consuming and involves iterative steps. Thus, to overcome this disadvantage, Vivonics Inc., a medical device company, developed and patented a one-step rapid technique named Rapid Isolation of DNA Aptamers (RIDA) for the isolation of high affinity and high selectivity aptamers. Such factors are expected to fuel the adoption of aptamers.

Market Dynamics

Increasing number of inorganic strategies such as license agreement by the key market players is expected to drive the global aptamers market over the forecast period. For instance, in September 2022, CAGE Bio Inc., a biotechnology company and TAGCyx Biotechnologies Inc., a research based company, announced that they had executed a license agreement for the development of TAGX-0003 for the treatment of Immuno dermatology diseases. Under this agreement, CAGE Bio Inc. will receive a license to develop the drug (TAGX-0003) and TAGCyx Biotechnologies Inc., will receive an upfront payment, sales milestone payments and sales related royalties. TAGX-0003 is a DNA aptamer that possess potent interferon gamma antagonistic activity which penetrates into the skin enabling a non-invasive, efficacious and safe treatment for dermatological diseases.

Key features of the study:

• This report provides an in-depth analysis of the global aptamers market, and provides market size (US$ Million) and compound annual growth rate (CAGR%) for the forecast period (2022–2030), considering 2021 as the base year
• It elucidates potential revenue opportunities across different segments and explains attractive investment proposition matrices for this market
• This study also provides key insights about market drivers, restraints, opportunities, new product launches or approval, market trends, regional outlook, and competitive strategies adopted by key players
• It profiles key players in the global aptamers market based on the following parameters – company highlights, products portfolio, key highlights, financial performance, and strategies
• Key companies covered as a part of this study include Ophthotech Corporation, Aptamer Sciences, Inc., Novartis AG, NeoNeuro SAS, Aptagen LLC, Aptus Biotech S.L., AM Biotechnologies, LLC, Base Pair Biotechnologies, Vivonics Inc., CAGE Bio Inc., TAGCyx Biotechnologies Inc., AstraZeneca, GlyTech, Inc., GC Biopharma Corp., Achiko AG, Agilent Technologies, Inc., SomaLogic Operating Co., Inc., Amsbio, and IVERIC bio, Inc.,
• Insights from this report would allow marketers and the management authorities of the companies to make informed decisions regarding their future product launches, type up-gradation, market expansion, and marketing tactics
• The global aptamers market report caters to various stakeholders in this industry including investors, suppliers, product manufacturers, distributors, new entrants, and financial analysts
• Stakeholders would have ease in decision-making through various strategy matrices used in analyzing the global aptamers market

Detailed Segmentation:

• Global Aptamers Market, By Type:
• Nucleic Acid Aptamers
• DNA-based Aptamers
• RNA-based Aptamers
• XNA-based Aptamers
• Peptide Aptamers
• Global Aptamers Market, By Application:
• Diagnostics
• Therapeutics
• Research and Development
• Global Aptamers Market, By End User:
• Biotechnology and Pharmaceutical Companies
• Academic and Research Institutions
• Contract Research Organization
• Global Aptamers Market, By Region:
• North America
• By Country
• U.S.
• Canada
• Latin America
• By Country
• Brazil
• Mexico
• Argentina
• Rest of Latin America
• Europe
• By Country
• Germany
• U.K.
• France
• Italy
• Spain
• Russia
• Rest of Europe
• Asia Pacific
• By Country
• China
• India
• Japan
• Australia
• South Korea
• ASEAN
• Rest of Asia Pacific
• Middle East
• By Country
• GCC
• Israel
• Rest of Middle East
• Africa
• By Country
• South Africa
• Central Africa
• North Africa
• Company Profiles
• Ophthotech Corporation*
• Company Highlights
• Products Portfolio
• Key Highlights
• Financial Performance
• Strategies
• Aptamer Sciences, Inc.
• Novartis AG
• NeoNeuro SAS
• Aptagen, LLC
• Aptus Biotech S.L.
• AM Biotechnologies, LLC
• Base Pair Biotechnologies
• Vivonics Inc.
• CAGE Bio Inc.
• TAGCyx Biotechnologies Inc.
• AstraZeneca
• GlyTech, Inc.
• GC Biopharma Corp.
• Achiko AG
• Agilent Technologies, Inc.
• SomaLogic Operating Co., Inc.
• Amsbio
• IVERIC bio, Inc.

“*” marked represents similar segmentation in other categories in the respective section.